SCHEMBL5543873

SCHEMBL5543873

N#Cc1ccc(C(=O)NCCCCCCCNC(=O)c2ccc(C#N)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.67
HDAC3 O15379 1/20 0.62
HDAC1 Q13547 1/20 0.62
SIGMAR1 Q99720 2/20 0.59
MAPK1 P28482 1/20 0.59
EPHX2 P34913 2/20 0.57
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
TMEM97 Q5BJF2 1/20 0.55
DPP4 P27487 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CCR3 P51677 1/20 0.54
CD274 Q9NZQ7 1/20 0.53
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
MGLL Q99685 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20707157 1.00 NAMPT (0.67) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL5546309 1.00 NAMPT (0.67) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL5515823 1.00 NAMPT (0.67) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL5536198 0.98 NAMPT (0.64) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL19133513 0.94 NAMPT (0.61) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL28929238 0.92 L3MBTL1 (0.68) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL22265515 0.92 L3MBTL1 (0.68) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL19133485 0.92 HDAC3 (0.62) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL7391759 0.92 POLB (0.60) NAMPTHDAC3HDAC1SIGMAR1MAPK1
SCHEMBL17623676 0.90 SIGMAR1 (0.60) NAMPTHDAC3HDAC1SIGMAR1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262223-B2 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-28 US disclosed
US-7262223-B2 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-28 US disclosed
EP-1715857-A1 AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS Neurochem (International) Limited (CH) 2006-11-02 EP disclosed
WO-2005079780-A1 AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-09-01 WO disclosed
US-20050182118-A1 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182118-A1 Amidine derivatives for treating amyloidosis APP, IAPP, GRN NAMPT 131/4885HDAC3 3707/4885HDAC1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.